• Ahmed, S.F., Sohail, M.S., Quadeer, A.A., McKay, M.R., 2022. Vaccinia-virus-based vaccines are expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus. Viruses 14, 1960.

  • Benhnia, M.R., McCausland, M.M., Laudenslager, J., Granger, S.W., Rickert, S., Koriazova, L., Tahara, T., Kubo, R.T., Kato, S., Crotty, S., 2009. Heavily isotypedependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J. Virol. 83, 12355-12367.

  • Breman, J.G., Kalisa, R., Steniowski, M.V., Zanotto, E., Gromyko, A.I., Arita, I., 1980. Human monkeypox, 1970-79. Bull. World Health Organ. 58, 165-182.

  • Earl, P.L., Americo, J.L., Wyatt, L.S., Eller, L.A., Whitbeck, J.C., Cohen, G.H., Eisenberg, R.J., Hartmann, C.J., Jackson, D.L., Kulesh, D.A., Martinez, M.J., Miller, D.M., Mucker, E.M., Shamblin, J.D., Zwiers, S.H., Huggins, J.W., Jahrling, P.B., Moss, B., 2004. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428, 182-185.

  • Edghill-Smith, Y., Golding, H., Manischewitz, J., King, L.R., Scott, D., Bray, M., Nalca, A., Hooper, J.W., Whitehouse, C.A., Schmitz, J.E., Reimann, K.A., Franchini, G., 2005. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11, 740-747.

  • Fang, Q., Yang, L., Zhu, W., Liu, L., Wang, H., Yu, W., Xiao, G., Tien, P., Zhang, L., Chen, Z., 2005. Host range, growth property, and virulence of the smallpox vaccine:vaccinia virus Tian Tan strain. Virology 335, 242-251.

  • Gilchuk, I., Gilchuk, P., Sapparapu, G., Lampley, R., Singh, V., Kose, N., Blum, D.L., Hughes, L.J., Satheshkumar, P.S., Townsend, M.B., Kondas, A.V., Reed, Z., Weiner, Z., Olson, V.A., Hammarlund, E., Raue, H.P., Slifka, M.K., Slaughter, J.C., Graham, B.S., Edwards, K.M., Eisenberg, R.J., Cohen, G.H., Joyce, S., Crowe Jr., J.E., 2016. Crossneutralizing and protective human antibody specificities to poxvirus infections. Cell 167, 684-694 e689.

  • Golden, J.W., Josleyn, M., Mucker, E.M., Hung, C.F., Loudon, P.T., Wu, T.C., Hooper, J.W., 2012. Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates. PLoS One 7, e42353.

  • Heraud, J.M., Edghill-Smith, Y., Ayala, V., Kalisz, I., Parrino, J., Kalyanaraman, V.S., Manischewitz, J., King, L.R., Hryniewicz, A., Trindade, C.J., Hassett, M., Tsai, W.P., Venzon, D., Nalca, A., Vaccari, M., Silvera, P., Bray, M., Graham, B.S., Golding, H., Hooper, J.W., Franchini, G., 2006. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177, 2552-2564.

  • Hirao, L.A., Draghia-Akli, R., Prigge, J.T., Yang, M., Satishchandran, A., Wu, L., Hammarlund, E., Khan, A.S., Babas, T., Rhodes, L., Silvera, P., Slifka, M., Sardesai, N.Y., Weiner, D.B., 2011. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J. Infect. Dis. 203, 95-102.

  • Kaever, T., Matho, M.H., Meng, X., Crickard, L., Schlossman, A., Xiang, Y., Crotty, S., Peters, B., Zajonc, D.M., 2016. Linear epitopes in vaccinia virus A27 are targets of protective antibodies induced by vaccination against smallpox. J. Virol. 90, 4334-4345.

  • Kaever, T., Meng, X., Matho, M.H., Schlossman, A., Li, S., Sela-Culang, I., Ofran, Y., Buller, M., Crump, R.W., Parker, S., Frazier, A., Crotty, S., Zajonc, D.M., Peters, B., Xiang, Y., 2014. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein. J. Virol. 88, 11339-11355.

  • Khlusevich, Y., Matveev, A., Emelyanova, L., Goncharova, E., Golosova, N., Pereverzev, I., Tikunova, N., 2022. New p35 (H3L) epitope involved in vaccinia virus neutralization and its deimmunization. Viruses 14, 1224.

  • Marriott, K.A., Parkinson, C.V., Morefield, S.I., Davenport, R., Nichols, R., Monath, T.P., 2008. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 26, 581-588.

  • Matho, M.H., Schlossman, A., Meng, X., Benhnia, M.R., Kaever, T., Buller, M., Doronin, K., Parker, S., Peters, B., Crotty, S., Xiang, Y., Zajonc, D.M., 2015. Structural and functional characterization of anti-A33 antibodies reveal a potent cross-species orthopoxviruses neutralizer. PLoS Pathog. 11, e1005148.

  • McCausland, M.M., Benhnia, M.R., Crickard, L., Laudenslager, J., Granger, S.W., Tahara, T., Kubo, R., Koriazova, L., Kato, S., Crotty, S., 2010. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir. Ther. 15, 661-675.

  • Moss, B., 2011. Smallpox vaccines:targets of protective immunity. Immunol. Rev. 239, 8-26.

  • Moss, B., 2012. Poxvirus cell entry:how many proteins does it take? Viruses 4, 688-707.

  • Parrino, J., Graham, B.S., 2006. Smallpox vaccines:past, present, and future. J. Allergy Clin. Immunol. 118, 1320-1326.

  • Pickup, D.J., 2015. Extracellular virions:the advance guard of poxvirus infections. PLoS Pathog. 11, e1004904.

  • Saijo, M., Ami, Y., Suzaki, Y., Nagata, N., Iwata, N., Hasegawa, H., Ogata, M., Fukushi, S., Mizutani, T., Sata, T., Kurata, T., Kurane, I., Morikawa, S., 2006. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J. Virol. 80, 5179-5188.

  • Sakhatskyy, P., Wang, S., Chou, T.H., Lu, S., 2006. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 355, 164-174.